Jul 17,2019

Abbott ramping up FreeStyle Libre production following bountiful Q2

The company's executives lauded the CGM system, which saw a 72.9% increase in organic sales during the last quarter, and hinted at implementations of the tech beyond diabetes alone. Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 10,2019

Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration

Nemaura Medical, Inc., a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it has submitted its De Novo 510(k) medical device application to the U.S. Food & Drug Administration for SugarBEAT® following the successful completion of clinical studies and two summative human factors usability studies for SugarBEAT®.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 23,2019

Medtronic Requests Approval of Non-Adjunctive Labeling from FDA

Medtronic plc(opens new window) (NYSE:MDT), the global leader in medical technology, services and solutions, today announced its Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) requesting approval for non-adjunctive labeling for its Guardian™ Sensor 3, as part of the MiniMed™ 670G system. If the FDA approves a sensor with non-adjunctive labeling, it means that a sensor is accurate enough to be used to calculate an insulin dose for meals and to correct high glucose levels. Since Medicare requires a non-adjunctive label for sensor reimbursement, if approved, this labeling could broaden patient access by allowing for Medicare coverage of the world’s first and still the only commercially available hybrid closed loop system.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 07,2019

Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch

Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced the first shipments of SugarBEAT® to diabetic and pre-diabetic patients in the United Kingdom. These shipments are part of the first phase of Nemaura Medical’s rollout program for SugarBEAT® following its recent CE mark approval in Europe.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 03,2019

Senseonics Announces Two Positive Blue Cross Blue Shield Coverage Decisions for Eversense CGM

Senseonics Holdings, Inc. a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Blue Cross Blue Shield of Massachusetts and Blue Cross Blue Shield of Idaho are now providing coverage for Eversense CGM. These recent coverage decisions add to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

COLLABORATION COLLABORATION

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 09,2019

Medtronic Announces Reimbursement in Germany for MiniMed™ 670G Insulin Pump System for Individuals with Type 1 Diabetes

Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today announced it has secured reimbursement for the MiniMed™ 670G insulin pump system with the German Federal Association of the Statutory Health Insurances (GKV-SV).

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 09,2019

Dexcom G6® CGM System Now Available In Canada

"We are thrilled to offer the Dexcom G6 Continuous Glucose Monitoring (CGM) System to Canadians and are proud of this innovative technology that enables more effective diabetes management," said Laura Endres, Vice President and General Manager, Dexcom Canada, Inc. "The Dexcom G6 not only frees people with diabetes from the burden of fingersticks, but also offers real-time alerts and other features that can help people make more informed decisions for their daily diabetes management. This product changes people's lives."

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 13,2019

ABBOTT'S REVOLUTIONARY FREESTYLE® LIBRE SYSTEM NOW REIMBURSED IN THE TWO LARGEST PROVINCES IN CANADA

Abbott (NYSE: ABT), the global leader in sensor-based glucose monitoring, announced today that it has received public reimbursement in Ontario and Quebec for its FreeStyle® Libre system, becoming the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada. Quebec residents 18 years or older2 and Ontario residents using insulin are eligible for reimbursement under the public programs. With its proven accuracy and ease of use,3 the FreeStyle Libre system replaces traditional blood glucose monitoring and allows patients to dose insulin based on the results.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 16,2019

ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED

Abbott (NYSE: ABT) and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with Sanofi′s insulin dosing information for future smart pens, insulin titration apps and cloud software.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Sep 16,2019

Medtronic and Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes

Medtronic plc, and Novo Nordisk A/S today announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic, such as the Guardian™ Connect system.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM